Fig. 1

Eplerenone attenuates SuHx-induced PH and pulmonary vascular remodeling. Preventive Eplerenone administration (Inspra®, 0.1% mixed in chow) to mice attenuated the development of SuHx-induced RV hypertrophy (RV/BW, mg/g; a) and increased RV systolic pressure (RVSP, mmHg; b). Total pulmonary resistance index (TPRi, ml^− 1∙min^− 1∙g^− 1; c) and systemic blood pressure (systemic BP, mmHg; d) remained unaltered by Eplerenone administration. Representative lung sections stained for Alcian Blue Elastic van Gieson (ABEVG), smooth muscle actin (SMA) and von Willebrand factor (vWF) are shown in e. Medial hypertrophy is presented as ratio of media to cross sectional area [CSA] (f). Remodeling of pulmonary blood vessels is demonstrated by muscularization (percentage of vessels). n = 5–10 mice per group; *: p < 0.05 vs. cntrl; †: p < 0.05 vs. SuHx